Web: www.taiclone.com
Tel: +886-2-2735-9682
Email: order@taiclone.com

AEE788

Catalog No: tcsc1452

Available Sizes

Size: 5mg

Size: 10mg

Size: 50mg

Specifications

CAS No:
497839-62-0

Formula:
$C_{27}H_{32}N_6$

Pathway:
JAK/STAT Signaling;Protein Tyrosine Kinase/RTK

Target:
EGFR;EGFR

Purity / Grade:
>98%

Solubility:
10 mM in DMSO

Alternative Names:
NVP-AEE 788

Observed Molecular Weight:
440.58

Product Description

Web: www.taiclone.com
Tel: +886-2-2735-9682
Email: order@taiclone.com

AEE788 is an inhibitor of the **EGFR** and **ErbB2** with **IC_{50}** values of 2 and 6 nM, respectively.

IC50 & Target: IC50: 2 nM (EGFR), 6 nM (ErbB2)[1]

In Vitro: AEE788 inhibits EGFR and VEGF receptor tyrosine kinases in the nM range (IC_{50}:EGFR 2 nm, ErbB2 6 nm, KDR 77 nm, and Flt-1 59 nm). In cells, growth factor-induced EGFR and ErbB2 phosphorylation is also efficiently inhibited (IC_{50}:11 and 220 nm, respectively). AEE788 demonstrates antiproliferative activity against a range of EGFR and ErbB2-overexpressing cell lines (including EGFRvIII-dependent lines) and inhibits the proliferation of epidermal growth factor- and VEGF-stimulated human umbilical vein endothelial cells[1]. Treatment of cutaneous SCC cells with AEE788 leads to dose-dependent inhibition of EGFR and VEGFR-2 phosphorylation, growth inhibition, and induction of apoptosis[2].

In Vivo: AEE788 efficiently inhibits growth factor-induced EGFR and ErbB2 phosphorylation in tumors for >72 h. AEE788 also inhibits VEGF-induced angiogenesis in a murine implant model[1]. In mice treated with AEE788, tumor growth is inhibited by 54% at 21 days after the start of treatment compared with control mice[2].